MedPage Today on MSN
Mavacamten Poised to Expand to Pediatric Obstructive Hypertrophic Cardiomyopathy
The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...
For the fourth quarter of 2025, other revenues, net increased by $7.1 million, and site operating expenses increased by $5.4 million, in each case as compared to the fourth quarter of 2024, resulting ...
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases ...
Net sales were $1.104 billion for the fourth quarter, compared to $1.283 billion in the prior year's fourth quarter. -- Selling, general and administrative ("SG&A") expenses were $241.5 million for ...
Correspondence to Dr Benjamin F Mentiplay, La Trobe Sport and Exercise Medicine Research Centre, La Trobe University, Melbourne, Victoria, Australia; b.mentiplay{at}latrobe.edu.au Objective To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results